We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.89B
AUM Growth
+$345M
(+14%)
Cap. Flow
-$69.9M
Cap. Flow
% of AUM
-2.42%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
133
New
31
Increased
28
Reduced
22
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Q32 Bio
QTTB
|
+$97.6M |
| 2 |
Centene
CNC
|
+$61.3M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$51.5M |
| 4 |
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
|
+$41.1M |
| 5 |
CVS Health
CVS
|
+$39.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$52.4M |
| 2 |
Glaukos
GKOS
|
+$51.5M |
| 3 |
Insulet
PODD
|
+$41.5M |
| 4 |
McKesson
MCK
|
+$38.1M |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$35.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.89% |
| 2 | Financials | 1.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Universal Health Services
UHS
$9.43B
| $31M | 1.07% |
262,000
+130,000
| +98% | +$15.4M |
|
27
Agios Pharmaceuticals
AGIO
$2.16B
| $29.9M | 1.04% |
366,000
+103,016
| +39% | +$7.96M |
|
28
Natera
NTRA
$37.5B
| $29.5M | 1.02% |
3,180,000
+259,144
| +9% | +$2.54M |
|
29
Acadia Healthcare
ACHC
$3.17B
| $29M | 1.01% |
741,016
| – | – |
|
|
AET
30
DELISTED
Aetna Inc
AET
| $27.9M | 0.97% |
+165,000
| New | +$29.6M |
|
|
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
| $27.6M | 0.96% |
3,788,540
-166,954
| -4% | -$1.47M |
|
|
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $27.5M | 0.95% |
697,194
-825,372
| -54% | -$32.1M |
|
33
Xencor
XNCR
$1.44B
| $26.5M | 0.92% |
882,462
+360,462
| +69% | +$9.42M |
|
|
AERI
34
DELISTED
Aerie Pharmaceuticals
AERI
| $26.3M | 0.91% |
484,055
| – | – |
|
35
argenx
ARGX
$57.4B
| $25.7M | 0.89% |
319,920
-46,041
| -13% | -$3.48M |
|
|
GWPH
36
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $25.4M | 0.88% |
225,452
-113,728
| -34% | -$14.3M |
|
|
DFBHU
37
DELISTED
DFB Healthcare Acquisitions Corp. Unit
DFBHU
| $25.1M | 0.87% |
+2,500,000
| New | +$25.2M |
|
|
XLRN
38
DELISTED
Acceleron Pharma
XLRN
| $24M | 0.83% |
615,000
| – | – |
|
|
ECYT
39
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $23.9M | 0.83% |
+2,627,540
| New | +$14.5M |
|
|
WBA
40
DELISTED
Walgreens Boots Alliance
WBA
| $23.3M | 0.81% |
356,000
+211,000
| +146% | +$15.1M |
|
|
MLNT
41
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $23.1M | 0.8% |
+625,569
| New | +$41.1M |
|
|
AIMT
42
DELISTED
Aimmune Therapeutics
AIMT
| $22.6M | 0.78% |
+710,210
| New | +$25M |
|
|
BHVN
43
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $22.4M | 0.78% |
869,000
+528,000
| +155% | +$15.8M |
|
44
CytomX Therapeutics
CTMX
$705M
| $21.4M | 0.74% |
753,322
| – | – |
|
45
Gyre Therapeutics
GYRE
$662M
| $21.4M | 0.74% |
+110,747
| New | +$20.7M |
|
|
AAC
46
DELISTED
AAC Holdings
AAC
| $21.3M | 0.74% |
1,853,998
-19,278
| -1% | -$189K |
|
|
47
McKesson
MCK
$98.5B
| $21.1M | 0.73% |
150,000
-244,801
| -62% | -$38.1M |
|
|
OXFD
48
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $18M | 0.62% |
1,444,000
+180,000
| +14% | +$2.19M |
|
49
Alnylam Pharmaceuticals
ALNY
$36.3B
| $17.4M | 0.6% |
+146,000
| New | +$18.8M |
|
|
EPZM
50
DELISTED
Epizyme, Inc
EPZM
| $17.1M | 0.59% |
960,970
-48,556
| -5% | -$820K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q1 2018 Portfolio in Review
As of Q1 2018, Deerfield Management held 133 positions worth $2.89B, up 14% from $2.54B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Deerfield Management's Q1 2018 filing shows 31 new, 28 increased, 22 reduced and 15 closed positions. Its largest new stake was Q32 Bio: 290,391 shares worth $97.7M. The largest sale was DexCom, an estimated $52.4M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.
- Deerfield Management's largest Q1 2018 buy was Q32 Bio: 290,391 shares worth $97.7M.
- Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2018, an estimated $51.5M increase.
- Deerfield Management's biggest Q1 2018 reduction was DexCom, cutting an estimated $52.4M.
- Deerfield Management fully exited Revance Therapeutics, Inc. in Q1 2018, selling an estimated $35.8M.
- Deerfield Management's ten largest holdings make up 30% of its $2.89B portfolio in Q1 2018.
- Deerfield Management opened 31 new positions and closed 15 in Q1 2018.
- Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.89B.
Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.